CorMedix Inc. (NASDAQ: CRMD) is a pharmaceutical company that commercializes prescription drug products focused on hospital-administered anti-infectives and related therapeutic areas. Revenue is generated through product sales of its marketed drugs, including Defencath and MINOCIN IV, to hospital and healthcare institutional customers. CorMedix expanded its commercial portfolio substantially through the acquisition of Melinta Therapeutics, LLC on August 29, 2025, for total consideration of $453.7 million, which included contingent consideration of $95.9 million and intangible assets of $391.1 million. MINOCIN IV addresses the U.S. hospital anti-infectives market, targeting serious infections including multidrug-resistant Gram-negative organisms such as carbapenem-resistant Acinetobacter baumannii, which the CDC classified as an urgent antimicrobial resistance threat. The company carries convertible senior notes (4.00% due 2030, issued August 2025) on its balance sheet, reflecting a debt-financed acquisition structure. Joseph Todisco serves as Chief Executive Officer and Chairman of the Board, and Susan Blum serves as Chief Financial Officer, as of the 10-K filing dated March 5, 2026 (fiscal year ended December 31, 2025).

Revenue model

Product sales of FDA-approved prescription drugs to hospitals and healthcare institutions, with revenue dependent on third-party payor reimbursement and formulary inclusion. The Melinta Therapeutics acquisition (completed August 29, 2025) added marketed products that generate product royalties, reflected in contingent consideration tied to future sales performance.

Products and services

Defencath (catheter lock solution) and MINOCIN IV (intravenous minocycline for serious bacterial infections including CRAB). MINOCIN IV targets multidrug-resistant Gram-negative infections in hospital settings where oral therapy is not appropriate. Additional products and in-process R&D were acquired through the Melinta Therapeutics transaction (FY2025).

Customers and end markets

Hospital systems and healthcare institutions in the United States. End market demand is driven by the prevalence of serious hospital-acquired infections, including multidrug-resistant organisms. The CDC estimated carbapenem-resistant Acinetobacter baumannii caused approximately 8,500 infections and about 700 deaths annually in the U.S. during 2019-2020.

Value-chain role

Specialty pharmaceutical company operating as a commercial-stage drug marketer. Relies on third-party manufacturers for production and third-party payors for reimbursement. Antimicrobial stewardship protocols at hospitals influence prescribing decisions for MINOCIN IV.

Geographic exposure

United States primary commercial market, based on filing disclosures. International regulatory and reimbursement exposure referenced in risk factors but no specific international revenue breakdown disclosed in the excerpts.

Source: SEC 10-K, filed 2026-03-05

Industry: Pharmaceutical Preparations Peers: SEELOS THERAPEUTICS, INC. LeonaBio Inc DURECT CORP ImageneBio Inc Johnson & Johnson Paratek Pharmaceuticals, Inc. Trevi Therapeutics Inc TFF Pharmaceuticals, Inc. Verrica Pharmaceuticals Inc